奥浦迈: 国泰海通证券股份有限公司关于上海奥浦迈生物科技股份有限公司本次交易不构成《上市公司重大资产重组管理办法》第十三条规定的重组上市情形的核查意见

Core Viewpoint - The transaction by Shanghai Aopumai Biotechnology Co., Ltd. to acquire 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment does not constitute a major asset restructuring as per the relevant regulations [1][2][4]. Group 1: Transaction Details - The transaction involves the acquisition of 100% equity of Pengli Bio-pharmaceutical by issuing shares and cash to multiple investors [1][2]. - The company plans to raise supporting funds by issuing shares to no more than 35 specific investors [2]. Group 2: Regulatory Compliance - The independent financial advisor, Guotai Junan Securities Co., Ltd., conducted a review and confirmed that the transaction does not lead to a change in control of the company [4]. - The current controlling shareholder is Mr. Xiao Zhihua, and the actual controllers are Mr. Xiao and Mrs. He Yunfen, indicating stability in control post-transaction [4].